How Real-World Evidence Is Transforming Regulatory Decisions in Oncology and Rare Disease

Real-world evidence is reshaping how regulators evaluate therapies in oncology and rare disease. In areas where traditional trials are limited by small populations, ethical constraints, and rapidly evolving standards of care, RWE provides critical insight into how treatments perform in real clinical settings.

This post explores why RWE has become essential for approvals, label expansions, and postmarketing commitments, and what it takes to generate regulatory‑grade evidence that can withstand scrutiny.